Illumina reported third-quarter 2026 adjusted earnings of $1.44 per share, above the $1.36 forecast, and revenue of $1.17 billion, above the $1.15 billion consensus, according to the source. Shares closed the regular session at $290.06, up 0.44%, then fell 11.78% to $255.88 after the report.

Revenue grew 4.7% on an organic basis in rest-of-world markets, excluding currency and acquisitions. Adjusted EPS rose 7% from a year earlier. Adjusted operating margin reached 25%, which the company said was 100 basis points above its guidance.

Sequencing consumables revenue was $792 million, up 6% year over year. Sequencing instruments revenue was $106 million, down 2% on an organic basis. Sequencing services and other revenue was $158 million, up 8% organically.

Illumina raised its full-year 2026 guidance. Revenue is now expected between $4.64 billion and $4.66 billion, and EPS between $5.40 and $5.45 per diluted share. The company attributed the higher outlook to stronger sequencing consumables revenue from a larger NovaSeq X installed base. Fourth-quarter revenue guidance is $1.22 billion to $1.24 billion.

The source says the share decline came despite the beat and suggests investors may have wanted a larger guidance raise or stronger growth in some business lines. The source does not confirm the reason for the decline.

Chief Executive Jacob Thaysen said, "Our strategy is working, and I'm proud of what our team delivered for our customers and shareholders." Management said it will provide full 2027 guidance with its fourth-quarter results.